Financials Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Equities

600329

CNE000001808

Pharmaceuticals

End-of-day quote Shanghai S.E. 18:00:00 2024-06-23 EDT 5-day change 1st Jan Change
33.65 CNY -1.52% Intraday chart for Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited -4.54% 0.00%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 9,068 11,199 19,473 18,246 22,121 22,655 - -
Enterprise Value (EV) 1 9,068 11,199 19,473 18,246 22,121 22,655 22,655 22,655
P/E ratio 17.1 x 20.4 x 31.4 x 26.2 x 26.3 x 22.1 x 18.5 x 15.5 x
Yield 2.16% 1.71% - 3.85% 3.8% - - -
Capitalization / Revenue 1.3 x 1.7 x - 2.21 x 2.69 x 2.5 x 2.27 x 2.06 x
EV / Revenue 1.3 x 1.7 x - 2.21 x 2.69 x 2.5 x 2.27 x 2.06 x
EV / EBITDA 13.8 x - - 16.6 x 24.4 x 16.5 x 14 x 11.8 x
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Price to Book 1.98 x 2.33 x - 3.45 x 3.93 x 3.79 x 3.63 x 3.41 x
Nbr of stocks (in thousands) 768,873 773,643 773,443 773,443 770,158 770,158 - -
Reference price 2 13.86 17.52 31.41 29.10 33.65 33.65 33.65 33.65
Announcement Date 20-04-17 21-03-30 22-03-30 23-03-31 24-03-29 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 6,994 6,604 - 8,249 8,222 9,053 9,961 10,982
EBITDA 1 657 - - 1,099 906.4 1,370 1,618 1,924
EBIT 1 555.7 785.2 - 980 1,097 1,317 1,573 1,879
Operating Margin 7.95% 11.89% - 11.88% 13.34% 14.55% 15.79% 17.11%
Earnings before Tax (EBT) 1 743.1 768.1 - 980.2 1,095 1,318 1,573 1,879
Net income 1 625.6 661.7 769.1 861.8 986.7 1,173 1,399 1,672
Net margin 8.94% 10.02% - 10.45% 12% 12.96% 14.05% 15.23%
EPS 2 0.8100 0.8600 1.000 1.110 1.280 1.523 1.817 2.173
Free Cash Flow - - - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 0.3000 0.3000 - 1.120 1.280 - - -
Announcement Date 20-04-17 21-03-30 22-03-30 23-03-31 24-03-29 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - - - - - - -
ROE (net income / shareholders' equity) 12.1% 11.8% - 13.2% 15.1% 17.2% 19.7% 22.4%
ROA (Net income/ Total Assets) 8.37% - - - 9.68% 11.2% 13.6% 15.4%
Assets 1 7,474 - - - 10,194 10,475 10,288 10,859
Book Value Per Share 2 7.010 7.510 - 8.430 8.570 8.890 9.270 9.860
Cash Flow per Share 2 0.9500 0.8700 - 0.8800 0.8900 1.500 1.400 1.540
Capex 1 206 182 - 106 141 30 29 28
Capex / Sales 2.94% 2.76% - 1.29% 1.71% 0.33% 0.29% 0.25%
Announcement Date 20-04-17 21-03-30 22-03-30 23-03-31 24-03-29 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
33.65 CNY
Average target price
45.8 CNY
Spread / Average Target
+36.11%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 600329 Stock
  4. Financials Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited